Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | GSK3B | P49841 | 4/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | PLG | P00747 | 1/20 | 0.55 |
| ▸ | ELANE | P08246 | 1/20 | 0.55 |
| ▸ | CTSG | P08311 | 1/20 | 0.55 |
| ▸ | CMA1 | P23946 | 1/20 | 0.55 |
| ▸ | CTRC | Q99895 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydantoin SCHEMBL4914979 | 0.87 | GSK3A (0.77) | GSK3AGSK3BF2PLGELANE | |
| SCHEMBL20339296 | 0.84 | KMT2A (0.73) | GSK3AGSK3BF2PLGELANE | |
| SCHEMBL6293317 | 0.83 | KMT2A (0.73) | GSK3AGSK3BKMT2AMGLLMEN1 | |
| SCHEMBL30953279 | 0.83 | GSK3A (0.71) | GSK3AGSK3BKMT2AMEN1GAA | |
| SCHEMBL10559302 | 0.82 | GSK3A (0.70) | GSK3AGSK3BF2PLGELANE | |
| SCHEMBL8320050 | 0.81 | SMN1; SMN2 (0.73) | GSK3AGSK3BKMT2AMEN1GAA | |
| SCHEMBL5311390 | 0.81 | GSK3A (0.69) | GSK3AGSK3BKMT2AMGLLMEN1 | |
| SCHEMBL4455461 | 0.81 | GSK3A (0.69) | GSK3AGSK3BF2PLGELANE | |
| SCHEMBL4658933 | 0.81 | GSK3A (0.69) | GSK3AGSK3BF2PLGELANE | |
| SCHEMBL20339321 | 0.81 | GSK3A (0.69) | GSK3AGSK3BKMT2AMGLLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827434-A2 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | Amgen Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006060318-A2 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC. (US) | 2006-06-08 | — | — | WO | claimed |
| JP-2141281-A | — | — | None | — | — | JP | disclosed |
| US-20230042042-A1 | UNNATURAL AMINO ACIDS AND USES THEREOF | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2023-02-09 | — | — | US | disclosed |
| US-20200123146-A1 | HETEROCYCLIC INTEGRIN AGONISTS | GB006 INC (US) | 2020-04-23 | — | — | US | disclosed |
| US-20200123146-A1 | HETEROCYCLIC INTEGRIN AGONISTS | GB006 INC (US) | 2020-04-23 | — | — | US | disclosed |
| WO-2018126072-A1 | HETEROCYCLIC INTEGRIN AGONISTS | ADHAERE PHARMACEUTICALS, INC. (US) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018126072-A1 | HETEROCYCLIC INTEGRIN AGONISTS | ADHAERE PHARMACEUTICALS, INC. (US) | 2018-07-05 | — | — | WO | disclosed |
| CN-106279132-A | 2, 4-imidazoline diketone heterocyclic derivative and preparation method and application thereof | 四川大学华西医院 | 2017-01-04 | — | — | CN | disclosed |
| EP-2144885-B1 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI SA (FR) | 2016-06-29 | — | — | EP | disclosed |
| US-8735437-B2 | Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| EP-0177072-A2 | Preparation of amino acids from unsaturated hydantoins | STAUFFER CHEMICAL COMPANY (US) | 1986-04-09 | — | — | EP | disclosed |
| EP-0060610-B1 | HEXAHYDRO-TRANS- AND TETRAHYDROPYRIDOINDOLE NEUROLEPTIC AGENTS | PFIZER INC. (US) | 1985-09-04 | — | — | EP | disclosed |
| US-4464387-A | Insecticidal phenyl hydantoin compounds | BUFFALO COLOR CORP. (US) | 1984-08-07 | — | — | US | disclosed |
| US-4432978-A | NEUROLEPTIC AGENTS, TRANQUILIZERS | PFIZER INC. (US) | 1984-02-21 | — | — | US | disclosed |
| US-4431649-A | TRANQUILIZERS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4431646-A | TRANQUILIZERS; PSYCHOSIS; NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4427679-A | TRANQUILIZERS; PSYCHOLOGICAL DISORDERS | PFIZER INC. (US) | 1984-01-24 | — | — | US | disclosed |
| EP-0060610-A1 | Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents | PFIZER INC. (US) | 1982-09-22 | — | — | EP | disclosed |
| US-4337250-A | NEUROLEPTIC AGENTS | PFIZER INC. (US) | 1982-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230042042-A1 | UNNATURAL AMINO ACIDS AND USES THEREOF | DNPEP, BCAT2, BCAT1 | GSK3A 4580/4885GSK3B 4715/4885F2 1624/4885 |
| US-20200123146-A1 | HETEROCYCLIC INTEGRIN AGONISTS | ITGA1, ITGA4, ITGA2 | GSK3A 2812/4885GSK3B 2807/4885F2 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.